Latest news
Combining BTK and BCL2 Inhibitors in Mantle Cell Lymphoma: Eyre Weighs in on Where the Field Goes Next - The American Journal of Managed CareThe American Journal of Managed Care · Wed, 05 Aug 2026 20:31:11 GMTSymposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence - lymphomahub.comlymphomahub.com · Fri, 31 Jul 2026 07:00:00 GMTCuris Doses First Five Patients in TakeAim CLL Study - SahmSahm · Thu, 30 Jul 2026 07:00:00 GMTProcessa snaps up Vidya and its BTK inhibitor, raises $200M for mid-stage trials - FirstWord PHARMAFirstWord PHARMA · Wed, 29 Jul 2026 21:06:26 GMTSymposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs - lymphomahub.comlymphomahub.com · Wed, 29 Jul 2026 15:38:50 GMTProcessa acquires Vidya for potential rival to Rhapsido - Fierce BiotechFierce Biotech · Wed, 29 Jul 2026 14:10:16 GMTImugene’s allogeneic CAR-T shows early promise in patients who failed BTKi therapy - BiotechDispatchBiotechDispatch · Tue, 28 Jul 2026 00:16:54 GMTEmavusertib-Based Therapy Produces Responses in BTK Inhibitor–Treated Primary CNS Lymphoma - Pharmacy TimesPharmacy Times · Mon, 27 Jul 2026 19:52:26 GMT